Immunovant IMVT
NASDAQ IMVT
$34.24 +0.46 (+1.36%)
As of: Oct 1, 2026 · 2:06 PM EDT

Immunovant (IMVT) Preferred Stock Liabilities (2019)

Updated

Immunovant's Preferred Stock Liabilities came in at $108.42 million for fiscal Q2 2020 (quarter ended Sep 30, 2019), up 0.1% from the prior quarter.

Analysis

Immunovant (IMVT) Preferred Stock Liabilities (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Immunovant 6.97 Bn 6.97 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 108.42 Mn
Jun 30, 2019 108.30 Mn
API Access

Immunovant Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=IMVT&period=max&api_key=YOUR_API_KEY